The underlying myopathic changes observed in GFPT1-related congenital myasthenic syndrome (27) might also contribute to the lack of significant MGFA improvement, further emphasizing that this scale may not be the most appropriate tool to capture treatment effects in this scenario. The gene discussed is GFPT1; the disease is congenital myasthenic syndrome.